Light-Activated drug combo takes on recurrent head and neck cancer in major trial
Disease control
Recruiting now
This phase 3 trial tests whether a new treatment called ASP-1929 photoimmunotherapy (a light-activated drug) combined with the immunotherapy pembrolizumab works better than standard care for people with recurrent head and neck cancer that hasn't spread to other parts of the body.…
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC